{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05552755",
            "orgStudyIdInfo": {
                "id": "REC-4881-201"
            },
            "organization": {
                "fullName": "Recursion Pharmaceuticals Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Evaluate REC-4881 in Patients With FAP",
            "officialTitle": "A Phase 1b-2, Multicenter, Trial To Evaluate The Efficacy, Safety, Pharmacokintetics, And Pharmacodynamics Of REC-4881 in Patients With Familial Adenomatous Polyposis (FAP)",
            "acronym": "TUPELO",
            "therapeuticArea": [
                "Other"
            ],
            "study": "evaluate-rec-in-patients-with-fap"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-07-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-14",
            "studyFirstSubmitQcDate": "2022-09-20",
            "studyFirstPostDateStruct": {
                "date": "2022-09-23",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Recursion Pharmaceuticals Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a multicenter, two-part trial in participants with Familial Adenomatous Polyposis (FAP).",
            "detailedDescription": "This is a Phase 1b/2, trial to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of REC-4881 in participants with Familial Adenomatous Polyposis (FAP). This two-part study will treat participants with phenotypic classical FAP with disease involvement of the duodenum or the residual colon/rectum/pouch as the primary disease site.\n\nPart 1 of the study enrolled seven participants with FAP who are post-colectomy/proctocolectomy. Participants were randomized to Placebo or REC-4881.\n\nPart 2 of the study will treat participants with escalating dose levels of REC-4881 during the Dose Finding. Participates in Cohort Expansion will be treated with a dose(s) to determine the RP2D."
        },
        "conditionsModule": {
            "conditions": [
                "Familial Adenomatous Polyposis"
            ],
            "keywords": [
                "FAP",
                "familial adenomatous polyposis",
                "APC mutation",
                "adenomatous polyposis coli",
                "desmoid disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 73,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Placebo (Part 1)",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive placebo PO dosed once daily",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "REC-4881 4mg (Part 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive REC-4881 4mg PO dosed once daily",
                    "interventionNames": [
                        "Drug: REC-4881"
                    ]
                },
                {
                    "label": "REC-4881 4mg (Part 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive REC-4881 4mg PO dosed once daily",
                    "interventionNames": [
                        "Drug: REC-4881"
                    ]
                },
                {
                    "label": "REC-4881 8mg (Part 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive REC-4881 8mg PO dosed once daily",
                    "interventionNames": [
                        "Drug: REC-4881"
                    ]
                },
                {
                    "label": "REC-4881 12mg (Part 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive REC-4881 12mg PO dosed once daily",
                    "interventionNames": [
                        "Drug: REC-4881"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "REC-4881",
                    "description": "REC-4881 4mg capsules",
                    "armGroupLabels": [
                        "REC-4881 12mg (Part 2)",
                        "REC-4881 4mg (Part 1)",
                        "REC-4881 4mg (Part 2)",
                        "REC-4881 8mg (Part 2)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo capsules",
                    "armGroupLabels": [
                        "Placebo (Part 1)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Characterize plasma pharmacokinetic (PK) parameters of REC-4881",
                    "description": "Maximum (peak) plasma drug concentration (Cmax), time to reach maximum (peak) plasma concentration (Tmax), and area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "Assessed at multiple timepoints from Day 1 through 43 days in Part 1"
                },
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events",
                    "description": "Treatment Emergent Adverse Events, Serious Adverse Events, and treatment discontinuation and dose modification due to toxicity",
                    "timeFrame": "16 weeks (Part 2)"
                },
                {
                    "measure": "Evaluate totality of data to determine the Recommended Phase 2 Dose (RP2D)",
                    "description": "Determination of the RP2D",
                    "timeFrame": "16 weeks (Part 2)"
                },
                {
                    "measure": "Percent change from baseline in polyp burden",
                    "description": "Effect of REC-4881 on duodenal adenomas and rectal/pouch adenomas",
                    "timeFrame": "12 weeks (Part 2)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events",
                    "description": "Treatment Emergent Adverse Events, Serious Adverse Events, and treatment discontinuation and dose modification due to toxicity",
                    "timeFrame": "43 days (Part 1)"
                },
                {
                    "measure": "Characterize plasma pharmacokinetic (PK) parameters of REC-4881",
                    "description": "Maximum (peak) plasma drug concentration (Cmax), time to reach maximum (peak) plasma concentration (Tmax), and area under the plasma concentration-time curve (AUC)",
                    "timeFrame": "Assessed at multiple timepoints from Day 1 through Week 3 (Part 2)"
                },
                {
                    "measure": "Assess the effect of REC-4881 on polyp number, histological grade and disease score",
                    "description": "Change from baseline in polyp number, polyp number \\>5 mm, highest histological grade, spigelman stage classification for duodenal polyps, and inSiGHT stage for rectal/pouch polyps",
                    "timeFrame": "12 weeks (Part 2)"
                },
                {
                    "measure": "Assess the pharmacodynamic (PD) effect of REC-4881, and correlation between PD and clinical outcome",
                    "description": "Percent inhibition of pERK at multiple timepoints",
                    "timeFrame": "Day 1 through Week 3 (Part 2)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female and \u2265 55 years of age\n2. Have provided written informed consent to participate in the study\n3. Diagnosis of phenotypic classical FAP with disease involvement of the duodenum or the residual colon/rectum/pouch as the primary disease site.\n4. Genetic diagnosis of FAP with APC gene mutation (Part 2 only).\n5. Has undergone colectomy or subtotal colectomy\n6. No significant cardiovascular abnormalities\n7. Left ventricular ejection fraction of \\>50% as determined by echocardiogram\n8. No significant hematopoietic abnormalities\n9. No significant hepatic abnormalities\n10. No significant renal abnormalities\n11. Female participants must have a negative serum pregnancy test prior to Study Day 1\n12. All participants must be willing to follow the contraceptive guidance in the protocol\n13. Absence of gross blood in stool at Screening\n14. Participant must be willing to discontinue use of non-steroidal anti-inflammatory agents (NSAIDs) prior to Study Day 1\n\nExclusion Criteria:\n\n1. No clinically significant laboratory abnormality, medical or psychiatric illness\n2. Has had prior pelvic irradiation.\n3. Has gastrointestinal disease or recent gastrointestinal procedure that could interfere with oral absorption of REC-4881\n4. Has received treatment with other investigational agents prior to Study Day 1\n5. Treatment with other FAP-directed drug therapy within 8 weeks of screening endoscopy (Part 2 only).\n6. Is currently under treatment for desmoid tumors.\n7. Use of omega-3 fatty acids or oral corticosteroids prior to Study Day 1\n8. Use of strong CYP3A inhibitors or inducers prior to Study Day 1\n9. History of an ongoing or newly diagnosed eye abnormality.\n10. Cancer at screening endoscopy in GI tract (including stomach, duodenum, and colon/rectum/pouch) (Part 2 only).\n11. Has a large polyp (\\>1 cm) not amenable to complete removal\n12. Has active pancreatitis secondary to pancreatic duct obstruction\n13. Has active gall bladder disease\n14. Is pregnant, lactating or is planning to attempt to become pregnant during the study\n15. Has had major surgery prior to Study Day 1\n16. Has an active infection requiring systemic therapy.\n17. Has known hypersensitivity to the study drug or its excipients.\n18. History of alcohol or substance abuse.\n19. Received treatment with another MEK inhibitor prior to Screening\n20. Active or known HIV, hepatitis B or hepatitis C infections\n21. Has a severe or uncontrolled medical condition\n22. Use of strong BCRP or MRP2 inhibitors prior to Study Day 1\n23. Has clinically significant cardiovascular disease within 6 months of Day 1 including myocardial infarction or unstable angina, cardiac arrhythmias, uncontrolled hypertension, pulmonary embolism, QTcF prolongation, Congestive heart failure, Myocarditis or clinically significant pericarditis",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "55 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Recursion Pharmaceuticals",
                    "role": "CONTACT",
                    "phone": "385-374-1724",
                    "email": "clinicaltrials@recursionpharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Del Sol Research Management",
                    "status": "RECRUITING",
                    "city": "Tucson",
                    "state": "Arizona",
                    "zip": "85715",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Wendy Hotz, R.Ph.",
                            "role": "CONTACT",
                            "phone": "520-257-3881",
                            "email": "whotz@delsolresearch.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.22174,
                        "lon": -110.92648
                    }
                },
                {
                    "facility": "Medical Associates Research Group",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92123",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cainan Foltz, MD",
                            "role": "CONTACT",
                            "phone": "858-277-5678",
                            "email": "marg.office@marginc.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "GI Pros",
                    "status": "RECRUITING",
                    "city": "Naples",
                    "state": "Florida",
                    "zip": "34102",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Paula Allain",
                            "role": "CONTACT",
                            "phone": "239-649-1336",
                            "email": "pallainresearch@gmail.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.14234,
                        "lon": -81.79596
                    }
                },
                {
                    "facility": "Tandem Clinical Research",
                    "status": "RECRUITING",
                    "city": "Marrero",
                    "state": "Louisiana",
                    "zip": "70072",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gary Reiss, MD",
                            "role": "CONTACT",
                            "phone": "504-934-8424",
                            "email": "prescreen@tandemclinicalresearch.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.89937,
                        "lon": -90.10035
                    }
                },
                {
                    "facility": "University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Julie Starr",
                            "role": "CONTACT",
                            "phone": "215-349-8527",
                            "email": "jstarr@pennmedicine.upenn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute and University of Utah",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nathan Bybee",
                            "role": "CONTACT",
                            "phone": "801-646-4172",
                            "email": "Nathan.Bybee@hci.utah.edu"
                        },
                        {
                            "name": "Megan Keener",
                            "role": "CONTACT",
                            "phone": "801-585-6439",
                            "email": "Megan.Keener@hci.utah.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Benaroya Research Institute at Virginia Mason",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98101",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brooke Grubb",
                            "role": "CONTACT",
                            "phone": "206-341-1406",
                            "email": "brooke.grubb900@vmfh.org"
                        },
                        {
                            "name": "Emily Chesterfield",
                            "role": "CONTACT",
                            "email": "emily.chesterfield@vmfh.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011125",
                    "term": "Adenomatous Polyposis Coli"
                }
            ],
            "ancestors": [
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                },
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000018256",
                    "term": "Adenomatous Polyps"
                },
                {
                    "id": "D000000236",
                    "term": "Adenoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009386",
                    "term": "Neoplastic Syndromes, Hereditary"
                },
                {
                    "id": "D000044483",
                    "term": "Intestinal Polyposis"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14009",
                    "name": "Adenomatous Polyposis Coli",
                    "asFound": "Familial Adenomatous Polyposis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20368",
                    "name": "Fibromatosis, Aggressive",
                    "relevance": "LOW"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14011",
                    "name": "Polyps",
                    "relevance": "LOW"
                },
                {
                    "id": "M20402",
                    "name": "Adenomatous Polyps",
                    "relevance": "LOW"
                },
                {
                    "id": "M3591",
                    "name": "Adenoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M12331",
                    "name": "Neoplastic Syndromes, Hereditary",
                    "relevance": "LOW"
                },
                {
                    "id": "M25346",
                    "name": "Intestinal Polyposis",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T2191",
                    "name": "Familial Adenomatous Polyposis",
                    "asFound": "Familial Adenomatous Polyposis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4001",
                    "name": "MYH-associated Polyposis",
                    "asFound": "Familial Adenomatous Polyposis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1822",
                    "name": "Desmoid Tumor",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}